In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Biolife Solutions Inc (NASDAQ: BLFS) closed the day trading at $17.94 down -3.55% from the previous closing price of $18.60. In other words, the price has decreased by -$3.55 from its previous closing price. On the day, 0.59 million shares were traded. BLFS stock price reached its highest trading level at $18.3 during the session, while it also had its lowest trading level at $17.16.
Ratios:
For a better understanding of BLFS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.83 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on April 04, 2024, initiated with a Buy rating and assigned the stock a target price of $22.
On July 11, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $29.
Oppenheimer Upgraded its Perform to Outperform on April 25, 2022, while the target price for the stock was maintained at $28.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 22 ’24 when Aebersold Sarah sold 410 shares for $16.50 per share. The transaction valued at 6,765 led to the insider holds 65,085 shares of the business.
Wichterman Troy sold 956 shares of BLFS for $14,636 on Apr 18 ’24. The Chief Financial Officer now owns 126,658 shares after completing the transaction at $15.31 per share. On Apr 18 ’24, another insider, Mathew Aby J., who serves as the EVP & Chief Scientific Officer of the company, sold 584 shares for $15.31 each. As a result, the insider received 8,941 and left with 319,098 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLFS now has a Market Capitalization of 812682048 and an Enterprise Value of 833576000. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.67 while its Price-to-Book (P/B) ratio in mrq is 2.40. Its current Enterprise Value per Revenue stands at 5.818 whereas that against EBITDA is -18.426.
Stock Price History:
The Beta on a monthly basis for BLFS is 1.77, which has changed by -0.0005373359 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, BLFS has reached a high of $24.50, while it has fallen to a 52-week low of $8.92. The 50-Day Moving Average of the stock is 3.21%, while the 200-Day Moving Average is calculated to be 18.19%.
Shares Statistics:
Over the past 3-months, BLFS traded about 393.14K shares per day on average, while over the past 10 days, BLFS traded about 398990 shares per day. A total of 45.17M shares are outstanding, with a floating share count of 43.17M. Insiders hold about 4.71% of the company’s shares, while institutions hold 100.81% stake in the company. Shares short for BLFS as of 1713139200 were 3098458 with a Short Ratio of 7.88, compared to 1710460800 on 3034551. Therefore, it implies a Short% of Shares Outstanding of 3098458 and a Short% of Float of 10.34.
Earnings Estimates
Currently, 6.0 analysts are dedicated to thoroughly evaluating and rating the performance of Biolife Solutions Inc (BLFS) in the stock market.On average, analysts expect EPS of -$0.28 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.41, while EPS last year was -$0.32. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.09 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.27 and -$1.28 for the fiscal current year, implying an average EPS of -$0.9. EPS for the following year is -$0.45, with 4.0 analysts recommending between -$0.09 and -$0.69.
Revenue Estimates
8 analysts predict $26.01M in revenue for the current quarter. It ranges from a high estimate of $33.7M to a low estimate of $20.9M. As of the current estimate, Biolife Solutions Inc’s year-ago sales were $37.7MFor the next quarter, 8 analysts are estimating revenue of $24.19M. There is a high estimate of $35.3M for the next quarter, whereas the lowest estimate is $21.9M.
A total of 8 analysts have provided revenue estimates for BLFS’s current fiscal year. The highest revenue estimate was $146.8M, while the lowest revenue estimate was $95.79M, resulting in an average revenue estimate of $105.71M. In the same quarter a year ago, actual revenue was $143.27MBased on 6 analysts’ estimates, the company’s revenue will be $124.35M in the next fiscal year. The high estimate is $173.1M and the low estimate is $112M.
